We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cocrystal Pharma Inc | NASDAQ:COCP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.06 | 2.73% | 2.26 | 2.12 | 2.26 | 2.33 | 2.12 | 2.25 | 108,531 | 23:56:03 |
“We are pleased with our progress in 2020 in advancing our pipeline of novel antiviral compounds,” said Gary Wilcox, Ph.D., Chairman and Chief Executive Officer of Cocrystal. “We look forward to presenting at this conference and introducing upcoming milestones.”
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, hepatitis C viruses, coronaviruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
Investor Contact:LHA Investor RelationsJody Cain310-691-7100jcain@lhai.com
# # #
1 Year Cocrystal Pharma Chart |
1 Month Cocrystal Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions